Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019:57:60-62.
doi: 10.1016/j.ijscr.2019.02.028. Epub 2019 Feb 26.

Male DCIS diagnosed after use of over-the-counter hormonal supplement

S O Agbroko  1 , K E Rojas  2 , D M Manasseh  2 , P Borgen  2
Affiliations

Male DCIS diagnosed after use of over-the-counter hormonal supplement

S O Agbroko et al. Int J Surg Case Rep. 2019.

Abstract

Introduction: Male breast cancer is a rare disease. Although epidemiologic and genetic factors are associated with male breast cancer, hormonal factors may also play a role.

Case presentation: We report the case of a 39-year-old BRCA negative male patient taking a sexual performance enhancement supplement who presented with worsening asymmetric gynecomastia and unilateral spontaneous bloody nipple discharge and was found to have ductal carcinoma in-situ.

Discussion: The altered cellular environment related to the hormone contents of the supplement coincided with the rapid worsening of his gynecomastia and may have played a role in the development of the ductal carcinoma in-situ, or growth of an existing focus.

Conclusion: The use of hormonal male enhancement supplements can lead to higher levels of androgens in users. It is possible for this altered hormonal environment to cause the growth of tumor or promote the progression of an existing focus.

Keywords: Atypical ductal hyperplasia; Ductal carcinoma in-situ; Gynecomastia; Male breast cancer; Mastectomy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Ultrasound image of left retroareolar mass.
Fig. 2
Fig. 2
Left breast digital mammogram, ML view with biopsy clip.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Weir H.K., Thun M.J., Hankey B.F. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 2003;95(17):1276–1299. - PubMed
    1. Weiss Joli R., Moysich Kirsten B., Swede Helen. Epidemiology of male breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005;14(1):20–26. January 1. - PubMed
    1. Writing Group for the Women’s Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. - PubMed
    1. Agha R.A., Borrelli M.R., Farwana R., Koshy K., Fowler A., Orgill D.P., For the SCARE Group The SCARE 2018 statement: updating consensus surgical CAse REport (SCARE) guidelines. Int. J. Surg. 2018;(60):132–136. - PubMed
    1. Kenemans Peter, van der Mooren Marius J. Androgens and breast cancer risk. Gynecol. Endocrinol. 2012;28(sup1):46–49. - PubMed